Anaptysbio (ANAB) Appoints Daniel Faga to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
November 29, 2021 4:06 PM ESTSAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Mr. Daniel Faga to the companys Board of Directors.
Dan has extensive corporate strategy, finance and public company leadership experience in building world-class biopharmaceutical companies, said Hamza Suria, president and chief executive officer of AnaptysBio. His unique strategic vision is an exciting addition to our Board of Directors and we look forward to having Dans... More
